非定型溶血性尿毒症症候群治療の世界市場レポート 2025年

非定型溶血性尿毒症症候群治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で23億4,000万米ドルに成長します。予測期間中の成長は、政府の支援イニシアティブ、補体調節異常への注目、患者意識の高まり、治療法の利用可能性の増加、診断技術の向上などの要因によるものと考えられます。予測期間における主な動向には、次世代補体阻害剤、デジタルヘルスモニタリングとAIツール、AI主導の創薬、個別化医療、ジェノタイピングとバイオマーカーに基づく診断などがあります。

標的治療に対する需要の増加は、非定型溶血性尿毒症症候群（aHUS）治療市場の成長を促進すると予想されます。標的治療とは、疾患の進行に関与する分子経路に特異的に着目し、その経路を破壊する治療法です。これらの治療に対する需要が高まっているのは、より正確な治療をより少ない副作用で提供できるため、患者の転帰が改善し、従来の広範な治療に代わる選択肢を提供できるからです。非定型溶血性尿毒症症候群の場合、標的療法は、この疾患の主な原因である補体系の過剰活性化を阻害することによって機能します。これにより、血管や腎臓へのダメージを軽減する的確な介入が可能になります。例えば、2023年10月、NHSイングランドは、イングランドでホルモン補充療法（HRT）が1,100万件処方され、2021-22年から47％増加し、約230万人の患者が処方を受け、前年比29％増加したと報告しました。その結果、標的療法に対する需要の増加が非定型溶血性尿毒症症候群治療市場の成長を促進しています。

非定型溶血性尿毒症症候群治療市場の主なプレーヤーは、標的補体阻害を強化し、患者の転帰を改善するために、モノクローナル抗体医薬のような最先端の治療法の開発に注力しています。モノクローナル抗体は、疾患メカニズムに関与する特定のタンパク質を特異的に標的とし結合することで、有害な病原体と闘う免疫系の能力を模倣する、実験室で作製されたタンパク質です。例えば、2025年1月、インドのバイオ医薬品会社であるAstraZeneca Pharma India Limitedは、インドにおけるエクリズマブ（ソリリスとして販売）の輸入、販売、流通の承認を中央医薬品標準管理機構（CDSCO）から取得しました。このモノクローナル抗体は補体タンパク質C5に特異的に結合し、その切断を阻止することにより、免疫介在性細胞障害の原因となる末端補体複合体の形成を阻害します。エクリズマブは、補体介在性障害を阻止することにより、発作性夜間ヘモグロビン尿症（PNH）、非定型溶血性尿毒症症候群（aHUS）、全身性重症筋無力症、視神経脊髄炎スペクトラム障害などの稀で重篤な疾患の治療に使用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非定型溶血性尿毒症症候群治療のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非定型溶血性尿毒症症候群治療市場：成長率分析
• 世界の非定型溶血性尿毒症症候群治療市場の実績：規模と成長、2019～2024年
• 世界の非定型溶血性尿毒症症候群治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の非定型溶血性尿毒症症候群治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非定型溶血性尿毒症症候群治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 補体阻害薬
• 血漿交換療法
• 支持療法
• 抗生物質
• 世界の非定型溶血性尿毒症症候群治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 静脈内
• 皮下
• 経口
• 世界の非定型溶血性尿毒症症候群治療市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝子検査・診断ツール
• リアルタイムモニタリング・補体活性化技術
• 治療提供システム
• デジタルヘルスソリューション
• 世界の非定型溶血性尿毒症症候群治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• ホームケア設定
• 外来診療センター
• 世界の非定型溶血性尿毒症症候群治療市場：補体阻害薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エクリズマブ
• ラブリズマブ
• C5阻害剤
• H因子阻害剤
• その他
• 世界の非定型溶血性尿毒症症候群治療市場：血漿交換療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 新鮮凍結血漿（FFP）交換
• 治療用血漿交換（TPE）
• 血漿濾過
• その他
• 世界の非定型溶血性尿毒症症候群治療市場：支持療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 透析
• 腎臓移植
• 赤血球輸血
• 血小板輸血
• 抗凝固薬
• その他
• 世界の非定型溶血性尿毒症症候群治療市場：抗生物質のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 広域スペクトル抗生物質
• 標的抗生物質
• 予防的抗生物質
• その他

第7章 地域別・国別分析

• 世界の非定型溶血性尿毒症症候群治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の非定型溶血性尿毒症症候群治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非定型溶血性尿毒症症候群治療市場：競合情勢
• 非定型溶血性尿毒症症候群治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Chugai Pharmaceutical Co. Ltd.
• Alnylam Pharmaceuticals Inc.
• Vifor Pharma Ltd.
• Samsung Bioepis Co. Ltd.
• Fuji Pharma Co. Ltd.
• Aevitas Therapeutics Inc.
• Pharmasyntez JSC
• Omeros Corporation
• ChemoCentryx Inc.
• ISU Abxis Co. Ltd.
• Greenovation Biotech GmbH
• Akari Therapeutics plc
• NovelMed Therapeutics Inc.
• Eleva GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非定型溶血性尿毒症症候群治療市場2029年：新たな機会を提供する国
• 非定型溶血性尿毒症症候群治療市場2029年：新たな機会を提供するセグメント
• 非定型溶血性尿毒症症候群治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening condition marked by abnormal blood clotting, which leads to damage in small blood vessels and results in hemolytic anemia, low platelet count, and kidney injury. It is often caused by genetic mutations or dysregulation in the complement system, leading to uncontrolled inflammation and vascular damage.

The main treatment options for atypical hemolytic uremic syndrome include complement inhibitors, plasma exchange therapy, supportive care, and antibiotics. Complement inhibitors are therapeutic agents that block or modulate the activation of the complement system, a critical component of the immune system involved in inflammation, immune response, and cell lysis. These inhibitors are administered through various routes, such as intravenous, subcutaneous, and oral. Technologies involved in the treatment include genetic testing and diagnostic tools, real-time monitoring and complement activation technologies, treatment delivery systems, and digital health solutions. These are used in various healthcare settings, including specialty clinics, home care environments, and ambulatory care centers.

The atypical hemolytic uremic syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides atypical hemolytic uremic syndrome treatment market statistics, including atypical hemolytic uremic syndrome treatment industry global market size, regional shares, competitors with atypical hemolytic uremic syndrome treatment market share, detailed atypical hemolytic uremic syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the atypical hemolytic uremic syndrome treatment industry. This atypical hemolytic uremic syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atypical hemolytic uremic syndrome treatment market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to several factors, including an increase in clinical trials, growing awareness of the disease, government support for research, enhanced diagnostic capabilities, and a rising incidence of the disease.

The atypical hemolytic uremic syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to factors such as government support initiatives, a focus on complement dysregulation, growing patient awareness, increased availability of treatments, and improved diagnostic techniques. Key trends in the forecast period include next-generation complement inhibitors, digital health monitoring and AI tools, AI-driven drug discovery, personalized medicine, and genotyping and biomarker-based diagnostics.

The increasing demand for targeted therapies is expected to drive the growth of the atypical hemolytic uremic syndrome (aHUS) treatment market. Targeted therapies are medical treatments that specifically focus on and disrupt the molecular pathways involved in disease progression. The growing demand for these therapies stems from their ability to deliver more precise treatments with fewer side effects, leading to improved patient outcomes and offering alternatives to traditional, broader treatments. In the case of atypical hemolytic uremic syndrome, targeted therapies work by blocking the overactivation of the complement system, which is the primary cause of the disease. This allows for precise interventions that reduce damage to blood vessels and kidneys. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England, a 47% increase from 2021-22, with approximately 2.3 million patients receiving prescriptions, marking a 29% year-on-year rise. Consequently, the increasing demand for targeted therapies is fueling the growth of the atypical hemolytic uremic syndrome treatment market.

Key players in the atypical hemolytic uremic syndrome treatment market are focusing on developing cutting-edge therapies, such as monoclonal antibody drugs, to enhance targeted complement inhibition and improve patient outcomes. Monoclonal antibodies are laboratory-engineered proteins that mimic the immune system's ability to combat harmful pathogens by specifically targeting and binding to certain proteins involved in disease mechanisms. For example, in January 2025, AstraZeneca Pharma India Limited, a biopharmaceutical company based in India, received approval from the Central Drugs Standard Control Organization (CDSCO) to import, sell, and distribute eculizumab (marketed as Soliris) in India. These monoclonal antibodies specifically bind to the complement protein C5, preventing its cleavage and thereby blocking the formation of the terminal complement complex responsible for immune-mediated cell damage. Eculizumab is used to treat rare and severe conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica spectrum disorder by preventing complement-mediated damage.

In October 2022, Amgen Inc., a US-based biotechnology company, acquired ChemoCentryx Inc. for approximately $3.7 billion. This acquisition is part of Amgen's strategy to expand its portfolio in the field of autoimmune and rare diseases by incorporating ChemoCentryx's innovative therapies and expertise in complement-based treatments. ChemoCentryx Inc., a US-based biopharmaceutical company, specializes in developing treatments for rare conditions, including atypical hemolytic uremic syndrome (aHUS).

Major players in the atypical hemolytic uremic syndrome treatment market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Alnylam Pharmaceuticals Inc., Vifor Pharma Ltd., Samsung Bioepis Co. Ltd., Fuji Pharma Co. Ltd., Aevitas Therapeutics Inc., Pharmasyntez JSC, Omeros Corporation, ChemoCentryx Inc., ISU Abxis Co. Ltd., Greenovation Biotech GmbH, Akari Therapeutics plc, NovelMed Therapeutics Inc., Eleva GmbH.

North America was the largest region in the atypical hemolytic uremic syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atypical hemolytic uremic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the atypical hemolytic uremic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atypical hemolytic uremic syndrome (aHUS) market consists of revenues earned by entities by providing services such as renal support and dialysis, genetic testing and counseling, long-term monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical hemolytic uremic syndrome (aHUS) market also includes sales of immunosuppressive therapies, plasma exchange equipment, dialysis machines, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atypical hemolytic uremic syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atypical hemolytic uremic syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atypical hemolytic uremic syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Complement Inhibitors; Plasma Exchange Therapy; Supportive Care; Antibiotics
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Technology: Genetic Testing And Diagnostic Tools; Realtime Monitoring And Complement Activation Technologies; Treatment Delivery Systems; Digital Health Solutions
• 4) By End User: Hospital; Speciality Clinics; Home care Settings; Ambulatory Care Centres
• Subsegments:
• 1) By Complement Inhibitors: Eculizumab; Ravulizumab; C5 Inhibitors; Factor H Inhibitors; Other Complement Inhibitors
• 2) By Plasma Exchange Therapy: Fresh Frozen Plasma (FFP) Exchange; Therapeutic Plasma Exchange (TPE); Plasma Filtration; Other Plasma Exchange Techniques
• 3) By Supportive Care: Dialysis; Kidney Transplantation; Red Blood Cell Transfusions; Platelet Transfusions; Anticoagulants; Other Supportive Therapies
• 4) By Antibiotics: Broad-Spectrum Antibiotics; Targeted Antibiotics; Prophylactic Antibiotics; Other Antibiotic Treatments
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atypical Hemolytic Uremic Syndrome Treatment Market Characteristics

3. Atypical Hemolytic Uremic Syndrome Treatment Market Trends And Strategies

4. Atypical Hemolytic Uremic Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Atypical Hemolytic Uremic Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Atypical Hemolytic Uremic Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Atypical Hemolytic Uremic Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Atypical Hemolytic Uremic Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Atypical Hemolytic Uremic Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Atypical Hemolytic Uremic Syndrome Treatment Total Addressable Market (TAM)

6. Atypical Hemolytic Uremic Syndrome Treatment Market Segmentation

• 6.1. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complement Inhibitors
• Plasma Exchange Therapy
• Supportive Care
• Antibiotics
• 6.2. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing And Diagnostic Tools
• Realtime Monitoring And Complement Activation Technologies
• Treatment Delivery Systems
• Digital Health Solutions
• 6.4. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Speciality Clinics
• Home care Settings
• Ambulatory Care Centres
• 6.5. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eculizumab
• Ravulizumab
• C5 Inhibitors
• Factor H Inhibitors
• Other Complement Inhibitors
• 6.6. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Plasma Exchange Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fresh Frozen Plasma (FFP) Exchange
• Therapeutic Plasma Exchange (TPE)
• Plasma Filtration
• Other Plasma Exchange Techniques
• 6.7. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dialysis
• Kidney Transplantation
• Red Blood Cell Transfusions
• Platelet Transfusions
• Anticoagulants
• Other Supportive Therapies
• 6.8. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Targeted Antibiotics
• Prophylactic Antibiotics
• Other Antibiotic Treatments

7. Atypical Hemolytic Uremic Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Atypical Hemolytic Uremic Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market

• 8.1. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Atypical Hemolytic Uremic Syndrome Treatment Market

• 9.1. China Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 9.2. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Atypical Hemolytic Uremic Syndrome Treatment Market

• 10.1. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Atypical Hemolytic Uremic Syndrome Treatment Market

• 11.1. Japan Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 11.2. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Atypical Hemolytic Uremic Syndrome Treatment Market

• 12.1. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market

• 13.1. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market

• 14.1. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 14.2. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market

• 15.1. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 15.2. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Atypical Hemolytic Uremic Syndrome Treatment Market

• 16.1. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Atypical Hemolytic Uremic Syndrome Treatment Market

• 17.1. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Atypical Hemolytic Uremic Syndrome Treatment Market

• 18.1. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Atypical Hemolytic Uremic Syndrome Treatment Market

• 19.1. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Atypical Hemolytic Uremic Syndrome Treatment Market

• 20.1. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market

• 21.1. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 21.2. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Atypical Hemolytic Uremic Syndrome Treatment Market

• 22.1. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Atypical Hemolytic Uremic Syndrome Treatment Market

• 23.1. North America Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 23.2. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Atypical Hemolytic Uremic Syndrome Treatment Market

• 24.1. USA Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 24.2. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Atypical Hemolytic Uremic Syndrome Treatment Market

• 25.1. Canada Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 25.2. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Atypical Hemolytic Uremic Syndrome Treatment Market

• 26.1. South America Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 26.2. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market

• 27.1. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market

• 28.1. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 28.2. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Atypical Hemolytic Uremic Syndrome Treatment Market

• 29.1. Africa Atypical Hemolytic Uremic Syndrome Treatment Market Overview
• 29.2. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Atypical Hemolytic Uremic Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape
• 30.2. Atypical Hemolytic Uremic Syndrome Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Atypical Hemolytic Uremic Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Chugai Pharmaceutical Co. Ltd.
• 31.3. Alnylam Pharmaceuticals Inc.
• 31.4. Vifor Pharma Ltd.
• 31.5. Samsung Bioepis Co. Ltd.
• 31.6. Fuji Pharma Co. Ltd.
• 31.7. Aevitas Therapeutics Inc.
• 31.8. Pharmasyntez JSC
• 31.9. Omeros Corporation
• 31.10. ChemoCentryx Inc.
• 31.11. ISU Abxis Co. Ltd.
• 31.12. Greenovation Biotech GmbH
• 31.13. Akari Therapeutics plc
• 31.14. NovelMed Therapeutics Inc.
• 31.15. Eleva GmbH

32. Global Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atypical Hemolytic Uremic Syndrome Treatment Market

34. Recent Developments In The Atypical Hemolytic Uremic Syndrome Treatment Market

35. Atypical Hemolytic Uremic Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Atypical Hemolytic Uremic Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer